PharmaSGP Holding SE (PSG.DE)
EUR 24.2
(1.68%)
EUR 24.2
(1.68%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 65.37 Million EUR | 7911.03% |
| 2022 | 816 Thousand EUR | 81500.0% |
| 2021 | 1000.00 EUR | -99.31% |
| 2020 | 145 Thousand EUR | 0.0% |
| 2019 | - EUR | -100.0% |
| 2018 | 249 Thousand EUR | 0.0% |
| 2017 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 247 Thousand EUR | -100.0% |
| 2024 Q1 | 65.45 Million EUR | 0.13% |
| 2023 Q4 | 65.37 Million EUR | 11511.01% |
| 2023 Q1 | 716 Thousand EUR | -12.25% |
| 2023 Q2 | 615 Thousand EUR | -14.11% |
| 2023 FY | 65.37 Million EUR | 7911.03% |
| 2023 Q3 | 563 Thousand EUR | -8.46% |
| 2022 Q3 | 909 Thousand EUR | -9.64% |
| 2022 Q1 | - EUR | -100.0% |
| 2022 FY | 816 Thousand EUR | 81500.0% |
| 2022 Q4 | 816 Thousand EUR | -10.23% |
| 2022 Q2 | 1 Million EUR | 0.0% |
| 2021 Q2 | 38 Thousand EUR | -67.8% |
| 2021 FY | 1000.00 EUR | -99.31% |
| 2021 Q4 | 1000.00 EUR | -66.67% |
| 2021 Q3 | 3000.00 EUR | -92.11% |
| 2021 Q1 | 118 Thousand EUR | -18.62% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 FY | 145 Thousand EUR | 0.0% |
| 2020 Q4 | 145 Thousand EUR | -24.08% |
| 2020 Q3 | 191 Thousand EUR | -23.29% |
| 2020 Q2 | 249 Thousand EUR | 0.0% |
| 2019 FY | - EUR | -100.0% |
| 2019 Q1 | - EUR | 0.0% |
| 2019 Q4 | - EUR | 0.0% |
| 2018 FY | 249 Thousand EUR | 0.0% |
| 2017 FY | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| MPH Health Care AG | 8.33 Million EUR | -684.44% |
| Apontis Pharma AG | 6 Million EUR | -989.5% |
| Dermapharm Holding SE | 950.7 Million EUR | 93.124% |
| Evotec SE | 477.11 Million EUR | 86.299% |
| MERCK Kommanditgesellschaft auf Aktien | 8.84 Billion EUR | 99.261% |
| SynBiotic SE | 2.89 Million EUR | -2159.245% |